申请人:Biogen MA Inc.
公开号:EP3663291A1
公开(公告)日:2020-06-10
The present invention relates to compounds of formula I:
and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
本发明涉及式 I 的化合物:
及其药学上可接受的盐、包含式 I 化合物的药物组合物,以及使用所述化合物、盐和组合物治疗与 CRM1 活性相关的各种疾病的方法。